Myasthenia Gravis (MG) is a rare, but not exceptional, autoimmune disease that is diagnosed (Prevalence) in one in seven thousand (1.33/10,000) to one in five thousand (2/10,000) of the population. On top of these existing cases, each year there are 15 new cases per 1,000,000 of the population (Incidence). In total, over a 5 year period, in Europe, U.S.A. and Japan alone, more than 250,000 diagnosed MG patients need treatments.

MG is characterized by muscular fatigue leading to extreme weakness. The fatigue is caused by the loss of ability to convert nerve impulses into muscle contraction. Underlying these symptoms is an autoimmune disease. The patient’s immune system produces antibodies that attack the docking sites, or receptors, on the nerve/muscle interface.

Current treatment options for MG consist of symptomatic and causal treatments.

At present, there is no cure on the market.